Table 3.

The cycle characteristics and reproductive outcomes of ART in BPES patients with and without FOXL2 mutations.

Characteristics	Mutation group	Nonmutation group	P
N	12	5
Gn starting dosage (IU)	229.17 ± 54.18	172.50 ± 22.36	0.042
Gn duration (days)	15.08 ± 4.54	10.00 ± 1.73	0.014
Total dosage of Gn (IU)	4926.25 ± 2073.73	2002.50 ± 648.22	0.008
E2 on trigger day (pg/mL)	1553.63 ± 1067.67	2768.00 ± 1039.91	0.048
No. of follicles >14mm on trigger day	4.83 ± 3.97	14.60 ± 6.19	0.001
No. of retrieved oocytes	2.75 ± 1.91	12.40 ± 6.19	0.001
No. of metaphase II oocytes	0.5 (0,3)	6 (3,16)	0.006
Maturation rate, % (n/N)	51.52% (17/33)	70.97% (44/62)	0.060
No. of fertilized oocytes	1 (0,2)	6 (2,8.5)	0.019
Fertilization rate, % (n/N)	42.42% (14/33)	43.55% (27/62)	0.916
No. of day 3 good-quality embryos	0 (0,0)	4 (1.5,4.5)	0.001
Day 3 good-quality embryos rate, % (n/N)	21.43% (3/14)	59.26% (16/27)	0.021
No. of good-quality blastocysts	0 (0,1)	2 (0.5,4)	0.037
Good-quality blastocysts rate, % (n/N)	28.57% (4/14)	40.74% (11/27)	0.443
Cancellation rate, % (n/N)	36.84% (7/19)	0 (0/5)	0.272

Data are expressed as the mean ± standard deviation or median (interquartile range).